Using sarilumab to safely restart cancer immunotherapy
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a drug called sarilumab (which calms certain parts of the immune system) can help patients safely restart their cancer immunotherapy after having immune-related side effects. It aims to reduce the risk that the side effect comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer and are taking (or have taken) an immunotherapy drug.
- You have an immune-related side effect—like joint pain, lung inflammation, or colitis—that your doctor says is due to immunotherapy and is mild to moderate (grade 1–3). Your doctor recommends restarting immunotherapy.
- Your side effect has improved to mild (grade 1) or better for at least one week. (If you have a hormonal side effect, you need lifelong hormone pills, but that's okay.)
- You haven't had a severe (grade 4) immune-related side effect, or any heart or brain immune-related side effect in the past.
- You're in generally good health, able to do light activity (ECOG 0–1), and have adequate blood counts and liver/kidney function.
- You're not currently on a high dose of steroids (more than 10 mg of prednisone daily) or certain immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects tissue samples and medical data from people with sarcoma who are receiving or will receive immunotherapy. Its goal is to learn more about how these treatments work against sarcoma.
This Phase 2 trial tests whether adding sarilumab (an immune-blocking medicine) to three immunotherapy medicines can shrink unresectable, advanced melanoma that cannot be removed with surgery. It aims to improve how well the immune system controls the cancer, especially in Stage III or Stage IV disease.
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
This trial tests sarilumab, an injected antibody that blocks a key protein involved in inflammation, for people with moderate-to-severe rheumatoid arthritis (RA) who haven't had success with standard treatments. The goal is to see if adding sarilumab can help control joint pain and swelling.
This trial tests a new drug (SAR445877) for people with advanced non-small cell lung cancer whose cancer continued to grow despite immunotherapy. It aims to see if this treatment can help when other options have stopped working.
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Hear when a new Any Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.